@article{1e99dc48b98d4ca6a575dcec35c2cb84,
title = "Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma",
abstract = "Esophageal adenocarcinoma (EAC) is a disease with dismal treatment outcomes. Response to neoadjuvant chemoradiation (CRT) varies greatly. Although the underlying mechanisms of CRT resistance are not identified, accumulating evidence indicates an important role for local antitumor immunity. To explore the immune microenvironment in relation to response to CRT we performed an in-depth analysis using multiplex immunohistochemistry, flow cytometry and mRNA expression analysis (NanoString) to generate a detailed map of the immunological landscape of pretreatment biopsies as well as peripheral blood mononuclear cells (PBMCs) of EAC patients. Response to CRT was assessed by Mandard{\textquoteright}s tumor regression grade (TRG), disease-free- and overall survival. Tumors with a complete pathological response (TRG 1) to neoadjuvant CRT had significantly higher tumor-infiltrating T cell levels compared to all other response groups (TRG 2–5). These T cells were also in closer proximity to tumor cells in complete responders compared to other response groups. Notably, immune profiles of near-complete responders (TRG 2) showed more resemblance to non-responders (TRG 3–5) than to complete responders. A high CD8:CD163 ratio in the tumor was associated with an improved disease-free survival. Gene expression analyses revealed that T cells in non-responders were Th2-skewed, while complete responders were enriched in cytotoxic immune cells. Finally, complete responders were enriched in circulating memory T cells. preexisting immune activation enhances the chance for a complete pathological response to neoadjuvant CRT. This information can potentially be used for future patient selection, but also fuels the development of immunomodulatory strategies to enhance CRT efficacy.",
keywords = "Tumor microenvironment, chemoradiation, esophageal cancer, immune response, liquid biopsy",
author = "Goedegebuure, {R. S. A.} and M. Harrasser and {de Klerk}, {L. K.} and {van Schooten}, {T. S.} and {van Grieken}, {N. C. T.} and M. Eken and Grifhorst, {M. S.} and N. Pocorni and Jordanova, {E. S.} and {van Berge Henegouwen}, {M. I.} and Pouw, {R. E.} and Verheul, {H. M. W.} and {van der Vliet}, {J. J.} and {van Laarhoven}, {H. W. M.} and Thijssen, {V. L. J. L.} and Bass, {A. J.} and {de Gruijl}, {T. D.} and S. Derks",
note = "Funding Information: Adam Bass has research support from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, U.S.A, which has also provided financial support for the study. Tanja D. de Gruijl has a consultant or advisory role in DCprime, Macrophage Pharma, Partner Tx, is a co-founder of LAVA Therapeutics, and receives research funding from Idera Pharmaceuticals. Mark I. van Berge Henegouwen has a consultant role for Medtronic, Johnson and Johnson, Alesi Surgical and Mylan. Unrestricted research funds from Olympus and Stryker. All fees are paid to the institution. Hanneke W.M. van Laarhoven has consultant or advisory role in BMS, Lilly, MSD, Nordic Pharma, Servier and receives research funding/medication: Bayer, BMS, Celgene, Janssen, Lilly, Merck, Nordic Pharma, Philips, Roche, Servier. Johannes J. van der Vliet is CSO at Lava Therapeutics. Funding Information: SD is supported by the Dutch Cancer Society, the Netherlands Organisation for Scientific Research (NWO) and Oncode Institute. MH is supported by Oncode Institute. Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, U.S.A has provided financial support for the study. O2 core facility (Elena de Miquel and Marko Popovic) for assisting with mIHC. Nursing staff from endoscopy (Ria van Huffel and Linda Penninx) and surgery (Nel de Vries, Loes Nooteboom) to help with patient inclusions. Publisher Copyright: {\textcopyright} 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.",
year = "2021",
doi = "https://doi.org/10.1080/2162402X.2021.1954807",
language = "English",
volume = "10",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "1",
}